Lantidra (donislecel) in type 1 diabetes: An in‐depth analysis of pharmacology, clinical effectiveness, safety, and the therapeutic role of the first <scp>FDA</scp> ‐approved allogeneic islet cell therapy
Lantidra is currently reserved for highly selected adult T1D people with problematic hypoglycaemia and labile glycaemia unresponsive to other optimized therapies, where benefits may outweigh risks. Future research aims to improve graft survival, minimize immunosuppression, and explore alternative cell sources to expand β-cell replacement therapies.
Authors
- Fulya Erendor (ORCID: https://orcid.org/0000-0002-0726-803X)
- Salih Şanlıoğlu (ORCID: https://orcid.org/0000-0001-8379-5678)
- Özğür Dandin (ORCID: https://orcid.org/0000-0002-7386-6871)
- Melike Aliciaslan
- Ezgi Erbasan
Institutions
- Akdeniz University (TR)
Publication Details
- Journal
- Diabetic Medicine
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1111/dme.70168
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00